Detalhe da pesquisa
1.
Future indications and clinical management for fecal microbiota transplantation (FMT) in immuno-oncology.
Semin Immunol
; 67: 101754, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37003055
2.
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial.
Lancet Oncol
; 22(5): 643-654, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33857412
3.
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial.
Lancet Oncol
; 22(5): 655-664, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33857414
4.
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma.
N Engl J Med
; 378(19): 1789-1801, 2018 May 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-29658430
5.
Phase I/II trial of Durvalumab plus Tremelimumab and stereotactic body radiotherapy for metastatic head and neck carcinoma.
BMC Cancer
; 19(1): 68, 2019 Jan 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-30642290
6.
Gut microbiome predicts gastrointestinal toxicity outcomes from chemoradiation therapy in patients with head and neck squamous cell carcinoma.
Oral Oncol
; 148: 106623, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-38006691
7.
Prognostic and predictive value of non-steroidal anti-inflammatory drugs in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma.
Eur J Cancer
; 201: 113585, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38402687
8.
Clinical and toxicity predictors of response and progression to temsirolimus in women with recurrent or metastatic endometrial cancer.
Gynecol Oncol
; 131(2): 315-20, 2013 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-23938374
9.
Primary malignant melanoma of the vagina: A case report.
Gynecol Oncol Rep
; 49: 101266, 2023 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-37727370
10.
Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination.
J Clin Oncol
; 41(1): 75-85, 2023 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35867951
11.
Prognostic and predictive value of metformin in the European Organisation for Research and Treatment of Cancer 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma.
Eur J Cancer
; 189: 112900, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37277264
12.
Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial.
Nat Med
; 29(8): 2121-2132, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37414899
13.
Upfront DPYD Genotyping and Toxicity Associated with Fluoropyrimidine-Based Concurrent Chemoradiotherapy for Oropharyngeal Carcinomas: A Work in Progress.
Curr Oncol
; 29(2): 497-509, 2022 01 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-35200545
14.
Helicobacter pylori serology is associated with worse overall survival in patients with melanoma treated with immune checkpoint inhibitors.
Oncoimmunology
; 11(1): 2096535, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35832043
15.
Prognostic and predictive value of ß-blockers in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma.
Eur J Cancer
; 165: 97-112, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35220182
16.
Five-Year Analysis of Adjuvant Pembrolizumab or Placebo in Stage III Melanoma.
NEJM Evid
; 1(11): EVIDoa2200214, 2022 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-38319852
17.
Spatially mapping the immune landscape of melanoma using imaging mass cytometry.
Sci Immunol
; 7(70): eabi5072, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35363543
18.
Real-world analyses of therapy discontinuation of checkpoint inhibitors in metastatic melanoma patients.
Sci Rep
; 10(1): 14607, 2020 09 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-32884119
19.
Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial.
J Clin Oncol
; 38(33): 3925-3936, 2020 11 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-32946353
20.
Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo: A Secondary Analysis of a Randomized Clinical Trial.
JAMA Oncol
; 6(4): 519-527, 2020 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31895407